Center for Medical Innovation, Biomedical Research Institute, Seoul National University Hospital, Seoul 03080, Korea.
Department of Surgery, Seoul National University College of Medicine, Seoul 03080, Korea.
Int J Mol Sci. 2018 Feb 7;19(2):502. doi: 10.3390/ijms19020502.
Next generation sequencing has accelerated the discovery of a variety of new fusion gene types in clinical breast cancer samples by analyzing cancer genomes and transcriptomes. Although previous studies have focused on a few clinically validated oncogenic fusion genes as diagnostic and therapeutic targets in breast cancer, a perspective consideration has not been given thus far for a plethora of breast cancer fusion genes, which are being newly identified at an overwhelmingly increasing pace. In this perspective review, we discuss diverse fusion gene types recently identified in a variety of breast cancer subtypes, including breast clinical cancer samples in TCGA (The Cancer Genome Atlas) database. This perspective review will confer fresh and promising guidance onto breast cancer surgeons, clinical oncologists, and tumor biologists in determining research directions for seeking and developing novel fusion gene biomarkers for breast cancer diagnostics and therapeutic treatment in upcoming years.
下一代测序通过分析癌症基因组和转录组，加速了在临床乳腺癌样本中发现各种新的融合基因类型。尽管之前的研究集中在少数经过临床验证的致癌融合基因上，作为乳腺癌的诊断和治疗靶点，但迄今为止，还没有考虑到大量新发现的乳腺癌融合基因，这些基因的发现速度正在以前所未有的速度增长。在本次观点综述中，我们讨论了在各种乳腺癌亚型中最近发现的不同融合基因类型，包括 TCGA（癌症基因组图谱）数据库中的乳腺癌临床癌症样本。本次观点综述将为乳腺癌外科医生、临床肿瘤学家和肿瘤生物学家提供新的、有前途的指导，以确定在未来几年内寻找和开发新型融合基因生物标志物用于乳腺癌诊断和治疗的研究方向。
